LPAR1, lysophosphatidic acid receptor 1, 1902

N. diseases: 145; N. variants: 11
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1867743
Disease: Premature coronary artery atherosclerosis
Premature coronary artery atherosclerosis 		0.010 Biomarker phenotype BEFREE Heterozygotes manifest from an early age with a markedly reduced HDL, LpA-I, apoC-III ratio and an increased TC/HDLc ratio which would predict a relatively increased risk of premature coronary artery disease, compared to their normal siblings. 8728325 1996
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 Biomarker phenotype BEFREE These observations suggest that Edg-2 may be a negative regulator for ovarian epithelial cell growth and metastasis. 10632375 1999
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.030 AlteredExpression disease BEFREE In contrast, levels of Edg-2, -3, and -5 were higher in OSEs than OCCs. 10537322 1999
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.030 AlteredExpression disease BEFREE In contrast, levels of Edg-2, -3, and -5 were higher in OSEs than OCCs. 10537322 1999
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.030 AlteredExpression disease BEFREE In contrast, levels of Edg-2, -3, and -5 were higher in OSEs than OCCs. 10537322 1999
CUI: C0007959
Disease: Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease 		0.010 GeneticVariation disease BEFREE As a first application to molecular genetic studies, they were used to exclude the Edg-2 gene in six families with phenotype of demyelinating Charcot-Marie-Tooth disease of unknown origin. 10384882 1999
CUI: C0598589
Disease: Inherited neuropathies
Inherited neuropathies 		0.010 Biomarker disease BEFREE Consequently, the human Edg-2 gene was studied to assess its possible contribution in inherited neuropathies. 10384882 1999
CUI: C0003126
Disease: Anosmia
Anosmia 		0.300 Biomarker phenotype CTD_human Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. 11087877 2000
CUI: C0018273
Disease: Growth Disorders
Growth Disorders 		0.300 Biomarker group CTD_human Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. 11087877 2000
CUI: C0376634
Disease: Craniofacial Abnormalities
Craniofacial Abnormalities 		0.300 Biomarker group CTD_human Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. 11087877 2000
CUI: C0553757
Disease: Olfaction Disorders
Olfaction Disorders 		0.300 Biomarker group CTD_human Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. 11087877 2000
CUI: C1510410
Disease: Sense of smell altered
Sense of smell altered 		0.300 Biomarker phenotype CTD_human Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. 11087877 2000
CUI: C2718076
Disease: Fetal Mummification
Fetal Mummification 		0.300 Biomarker phenotype CTD_human Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. 11087877 2000
CUI: C3888024
Disease: Cacosmia
Cacosmia 		0.300 Biomarker disease CTD_human Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. 11087877 2000
CUI: C0029463
Disease: Osteosarcoma
Osteosarcoma 		0.020 AlteredExpression disease BEFREE In this study, transient overexpression of Edg-2 sensitized MG63 human osteosarcoma cells to both LPA- and S1P-mediated stimulation of fibronectin matrix deposition and actin stress fiber formation. 10961347 2000
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone 		0.020 AlteredExpression disease BEFREE In this study, transient overexpression of Edg-2 sensitized MG63 human osteosarcoma cells to both LPA- and S1P-mediated stimulation of fibronectin matrix deposition and actin stress fiber formation. 10961347 2000
CUI: C1332986
Disease: Childhood Osteosarcoma
Childhood Osteosarcoma 		0.020 AlteredExpression disease BEFREE In this study, transient overexpression of Edg-2 sensitized MG63 human osteosarcoma cells to both LPA- and S1P-mediated stimulation of fibronectin matrix deposition and actin stress fiber formation. 10961347 2000
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 AlteredExpression phenotype BEFREE Overall expression of EDG2 receptor was unchanged in malignancy; however, increased EDG2 expression in individual samples correlated with lymphonodular metastasis (p = 0.01). 11291053 2001
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.060 AlteredExpression group BEFREE Overall expression of EDG2 receptor was unchanged in malignancy; however, increased EDG2 expression in individual samples correlated with lymphonodular metastasis (p = 0.01). 11291053 2001
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.060 AlteredExpression group BEFREE Overall expression of EDG2 receptor was unchanged in malignancy; however, increased EDG2 expression in individual samples correlated with lymphonodular metastasis (p = 0.01). 11291053 2001
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.010 Biomarker disease BEFREE Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus. 12370857 2002
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 AlteredExpression phenotype BEFREE In particular, reduced Edg-2 gene product expression was also confirmed in a group of 50 primary melanomas and unrelated metastases. 12702151 2003
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.030 AlteredExpression group BEFREE In particular, reduced Edg-2 gene product expression was also confirmed in a group of 50 primary melanomas and unrelated metastases. 12702151 2003
CUI: C0009375
Disease: Colonic Neoplasms
Colonic Neoplasms 		0.010 Biomarker group LHGDN Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. 12670925 2003
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.010 Biomarker disease BEFREE Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. 12670925 2003